Loading briefing details...
News Abstract
By: NewsAbstract Editorial Team
Topic: Business
March 30, 2026
OMNI CRS's survey highlights the critical need for proactive, data-driven patient recruitment. This shift from reactive measures to early intervention promises to enhance clinical trial predictability, reduce operational burdens, and accelerate the delivery of new therapies to patients, fundamentally improving industry efficiency.
STIRLING, NJ – OMNI CRS's inaugural Clinical Research Industry Survey offers critical insights into patient recruitment challenges. Findings indicate issues rarely appear suddenly, often surfacing when trial timelines are at risk, with lagging enrollment a primary signal. The survey underscores a strong demand for earlier, protocol-specific patient engagement to boost start-up predictability and ensure faster access to qualified patients.
The data points to a structural issue: recruitment difficulties stem from delayed visibility into enrollment performance and misalignment between study criteria and real-world patient populations. When enrollment lags, sites often resort to reactive measures like increased ad spend, which frequently fail to address root problems. The survey emphasizes that increasing spend alone is insufficient; sites need to access more qualified patients earlier to reduce screening burden and budget strain.
OMNI CRS advocates for earlier, proactive engagement with qualified patients to significantly improve recruitment predictability. Their model utilizes protocol-specific targeting, multichannel outreach, and multi-level patient engagement to minimize unqualified inquiries. This approach provides faster feedback, reduces unnecessary screening, and supports higher conversion rates, transforming reactive management into a more predictable, sustainable system.